Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a top… Read more
Grace Therapeutics, Inc. (GRCE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.050x
Based on the latest financial reports, Grace Therapeutics, Inc. (GRCE) has a cash flow conversion efficiency ratio of -0.050x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.15 Million) by net assets ($62.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Grace Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Grace Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Grace Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Grace Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Seafco Public Company Limited
BK:SEAFCO
|
0.073x |
|
Victoria Investama Tbk
JK:VICO
|
-0.086x |
|
Nasmed Ozel Saglik Hizmetleri Ticaret AS
IS:EGEPO
|
0.093x |
|
GreenMobility A/S
CO:GREENM
|
0.802x |
|
Taiwan Takisawa Technology Co Ltd
TWO:6609
|
0.026x |
|
Zimmite Taiwan Ltd
TWO:8435
|
0.059x |
|
Principal Capital Public Company Limited
BK:PRINC
|
0.003x |
|
Whiting Petroleum Corporation
PINK:WLLBW
|
0.052x |
Annual Cash Flow Conversion Efficiency for Grace Therapeutics, Inc. (2010–2025)
The table below shows the annual cash flow conversion efficiency of Grace Therapeutics, Inc. from 2010 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $66.61 Million | $-14.90 Million | -0.224x | -12.02% |
| 2024-03-31 | $61.74 Million | $-12.33 Million | -0.200x | +14.70% |
| 2023-03-31 | $67.95 Million | $-15.91 Million | -0.234x | -47.11% |
| 2022-03-31 | $108.27 Million | $-17.23 Million | -0.159x | +38.13% |
| 2021-03-31 | $55.66 Million | $-14.32 Million | -0.257x | +85.43% |
| 2020-03-31 | $12.99 Million | $-22.95 Million | -1.766x | +21.30% |
| 2019-03-31 | $11.04 Million | $-24.79 Million | -2.244x | -47.43% |
| 2018-03-31 | $6.37 Million | $-9.69 Million | -1.522x | -530.30% |
| 2016-03-31 | $20.09 Million | $-4.85 Million | -0.242x | -11.49% |
| 2015-03-31 | $26.56 Million | $-5.75 Million | -0.217x | -5.95% |
| 2014-03-31 | $29.91 Million | $-6.12 Million | -0.204x | +22.00% |
| 2013-03-31 | $9.50 Million | $-2.49 Million | -0.262x | +32.45% |
| 2012-03-31 | $14.55 Million | $-5.65 Million | -0.388x | -18.23% |
| 2011-03-31 | $5.83 Million | $-1.91 Million | -0.328x | +30.67% |
| 2010-03-31 | $4.02 Million | $-1.90 Million | -0.473x | -- |